Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Pediatric AML Molecular Relapse
NCT02450877Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Aug 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02450877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450877.